Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Ilmiah Medicamento Jurnal Kefarmasian Indonesia
Budiarti, Niky
Unknown Affiliation
Chemistry Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Safety and Efficacy of Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment of Malaria in Pregnancy: A Systematic Review of Randomized Controlled Trials Arief, Thendi Abdul; Pertiwi, Luthfiah; Budiarti, Niky; Da Costa, Yohanna Lawanda; Ambarsari, Paulina
Jurnal Kefarmasian Indonesia VOLUME 15, NUMBER 2, JULY-DECEMBER 2025
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Preventing malaria in pregnant women is crucial, especially for the safety of both the mother and the baby, particularly in malaria-endemic areas. Dihydroartemisinin-Piperaquine (DHP) is one of the options for Intermittent Preventive Treatment in pregnancy (IPTp). Although several previous studies have assessed DHP as a preventive antimalarial in pregnancy, this study systematically consolidates the most recent Randomized Controlled Trials (RCTs), reflecting new evidence and resistance trends to Sulfadoxine-Pyrimethamine (SP) across malaria-endemic regions. This study aims to review the safety and efficacy of DHP use during pregnancy. The methodology involved a comprehensive literature search from the databases PubMed, ScienceDirect, Google Scholar, and Cochrane, published in English from 2020 to 2024. Inclusion criteria encompassed double-blind RCT evaluating the use of DHP during pregnancy. Exclusion criteria included studies that did not involve pregnant women, did not use DHP, and study designs other than double-blind RCT. The initial search yielded 255 articles. After screening for duplicates, a total of 50 duplicates were removed. Ultimately, 5 articles were identified after screening titles, abstracts, and full texts. The analysis results indicate that IPTp DHP is more effective in reducing the incidence of malaria compared to IPTp SP. However, IPTp SP is safer to use than IPTp DHP due to fewer adverse effects. The use of DHP may be considered for IPTp in cases of SP resistance. This review provides an updated synthesis of recent RCTs focusing on the comparative safety and efficacy of DHP versus SP in IPTp of malaria in pregnancy, highlighting recent evidence in the context of emerging SP resistance.
Understanding the Safety Profile of Imatinib in Asian Chronic Myeloid Leukemia Patients: A Systematic Review Budiarti, Niky; Ikawati, Zullies; Nurrochmad, Arief; Arief, Thendi Abdul
Jurnal Ilmiah Medicamento Vol 12 No 1 (2026): Jurnal Ilmiah Medicamento (In progress)
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v12i1.13296

Abstract

Background: The treatment of chronic myeloid leukemia has advanced substantially since the introduction of tyrosine kinase inhibitors, particularly imatinib. However, adverse events associated with imatinib may affect adherence and quality of life, highlighting the importance of understanding safety outcomes across populations.Objective: This systematic review aimed to synthesize evidence on hematologic and non-hematologic adverse events associated with imatinib use among chronic myeloid leukemia patients in Asia.Methods: A systematic literature search was conducted in PubMed, Scopus, and ScienceDirect for studies published between January 2020 and July 2025. Eligible studies were synthesized narratively due to methodological heterogeneity. Adverse events were extracted as reported and graded using standardized toxicity criteria, and causality assessment was applied when available. Study quality was evaluated using established critical appraisal tools. Five studies from India, China, and Taiwan met the inclusion criteria.Results: The most frequent hematologic adverse event was anemia, followed by neutropenia and thrombocytopenia. Common non-hematologic adverse events included gastrointestinal symptoms, peripheral or periorbital edema, muscle cramps, and hyperpigmentation, with regional variations. Most events were mild to moderate (grades 1–2), while severe fluid retention, including pleural and pericardial effusions, was reported in isolated cases. No studies reported permanent discontinuation of imatinib due to adverse events.Conclusion: This review summarizes imatinib-related adverse events among chronic myeloid leukemia patients from selected Asian regions—East and South Asia, specifically India, China, and Taiwan—showing predominantly mild to moderate toxicities and providing practice-informed insights for clinical monitoring. However, the absence of data from other Asian regions precludes generalization to the entire Asian continent.
Co-Authors Ambarsari, Paulina Arief Nurrochmad Arief, Thendi Abdul Da Costa, Yohanna Lawanda Pertiwi, Luthfiah